A US bipartisan group of senators has reached a deal on capping the price of insulin at USD 35, Semafor reports

This bipartisan agreement to cap insulin prices at USD 35 has significant implications for the pharmaceutical sector, particularly for companies like Eli Lilly and Sanofi. It could pressure profit margins within the industry while also providing relief to consumers, potentially shifting the dynamics in healthcare regulations and impacting broader market sentiment toward pharmaceuticals and related equities.